| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dialysis |
* Chronic Disease Research Group, Minneapolis Medical Research Foundation, and Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota
Address correspondence to: Dr. Allan J. Collins, Chronic Disease Research Group, Minneapolis Medical Research Foundation, 914 South 8th Street, Suite S-206, Minneapolis, MN 55404. Phone: 612-347-5811; Fax: 612-347-5878; E-mail: acollins{at}cdrg.org
National payment policies target a hemoglobin range of 11 to 12.5 g/dl for patients with ESRD. However, clinical complications and provider practices may contribute to wide fluctuations over time. This study evaluated the frequency with which patients maintain stable hemoglobin levels below, within, and above the Centers for Medicare & Medicaid Services target range and assessed patterns of hemoglobin level change that resulted in large fluctuations across the target range during a 6-mo period. All hemodialysis patients who survived the first 6 mo of 2003, had Medicare as primary payer, and had Medicare outpatient erythropoietin claims in each of the first 6 mo of 2003 (n = 152,846) were studied. Six patient groups were defined on the basis of patterns of hemoglobin level fluctuation: Consistently low (<11 g/dl), consistently target range (11 to 12.5 g/dl), consistently high (
12.5 g/dl), low-amplitude fluctuation with low hemoglobin levels, low-amplitude fluctuation with high hemoglobin levels, and high-amplitude fluctuation. Only 10.3% of patients maintained stable hemoglobin levels during the 6 mo and only 6.5% in the target range. The consistently low group had the highest percentage of hospitalizations and the highest number of comorbid conditions. High-amplitude fluctuation was the most common pattern (39.5%), with hemoglobin levels falling below and rising above the target range during the 6-mo period. Hemoglobin levels in almost 90% of patients are in some degree of flux at any point in time, and the fluctuation is highly associated with clinical complications and provider practices.
This article has been cited by other articles:
|
|
 |
|
  A. Besarab, W. H. Horl, and D. Silverberg Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome Oncologist, September 1, 2009; 14(suppl_1): 22 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Boudville, O. Djurdjev, I. C. Macdougall, A. L.M. de Francisco, G. Deray, A. Besarab, P. E. Stevens, R. G. Walker, P. Urena, P. Inigo, et al. Hemoglobin Variability in Nondialysis Chronic Kidney Disease: Examining the Association with Mortality Clin. J. Am. Soc. Nephrol., July 1, 2009; 4(7): 1176 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Arneson, D. Zaun, Y. Peng, C. A. Solid, S. Dunning, and D. T. Gilbertson Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1378 - 1383. [Full Text] [PDF]
|
|
|
|
|
|
B. D. Bradbury, C. W. Critchlow, M. R. Weir, R. Stewart, M. Krishnan, and R. H. Hakim Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients Nephrol. Dial. Transplant., March 1, 2009; 24(3): 919 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Minutolo, P. Chiodini, B. Cianciaruso, A. Pota, V. Bellizzi, D. Avino, S. Mascia, S. Laurino, V. Bertino, G. Conte, et al. Epoetin Therapy and Hemoglobin Level Variability in Nondialysis Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 552 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kalantar-Zadeh and G. R. Aronoff Hemoglobin Variability in Anemia of Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2009; 20(3): 479 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Heung, B. A Mueller, and J. H Segal Optimizing Anemia Management in Hospitalized Patients with End-Stage Renal Disease Ann. Pharmacother., February 1, 2009; 43(2): 276 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. M. de Francisco, P. Stenvinkel, and S. Vaulont Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness NDT Plus, January 1, 2009; 2(suppl_1): i18 - i26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Brunelli, K. E. Lynch, E. D. Ankers, M. M. Joffe, W. Yang, R. I. Thadhani, and H. I. Feldman Association of Hemoglobin Variability and Mortality among Contemporary Incident Hemodialysis Patients Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1733 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Walker Erythropoietin Stimulating Agents and Epoetin Alfa Revisited: What's Really Relevant? Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 935 - 937. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Brookhart, S. Schneeweiss, J. Avorn, B. D. Bradbury, K. J. Rothman, M. Fischer, J. Mehta, and W. C. Winkelmayer The Effect of Altitude on Dosing and Response to Erythropoietin in ESRD J. Am. Soc. Nephrol., July 1, 2008; 19(7): 1389 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tomasello Anemia of Chronic Kidney Disease Journal of Pharmacy Practice, June 1, 2008; 21(3): 181 - 195. [Abstract] [PDF]
|
|
|
|
|
|
S. M. Brunelli, M. M. Joffe, R. K. Israni, W. Yang, S. Fishbane, J. S. Berns, and H. I. Feldman History-Adjusted Marginal Structural Analysis of the Association between Hemoglobin Variability and Mortality among Chronic Hemodialysis Patients Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 777 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Gilbertson, J. P. Ebben, R. N. Foley, E. D. Weinhandl, B. D. Bradbury, and A. J. Collins Hemoglobin Level Variability: Associations with Mortality Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 133 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Weiner, D. C. Miskulin, K. Seefeld, V. Ladik, P. G. Zager, A. K. Singh, H. K. Johnson, and K. B. Meyer Reducing versus Discontinuing Erythropoietin at High Hemoglobin Levels J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3184 - 3191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yang, R. K. Israni, S. M. Brunelli, M. M. Joffe, S. Fishbane, and H. I. Feldman Hemoglobin Variability and Mortality in ESRD J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3164 - 3170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Liu, V. S. Stoll, P. J. DeVries, C. G. Jakob, N. Xie, R. L. Simmer, S. E. Lacy, D. A. Egan, J. E. Harlan, R. R. Lesniewski, et al. A potent erythropoietin-mimicking human antibody interacts through a novel binding site Blood, October 1, 2007; 110(7): 2408 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. De Nicola, G. Conte, P. Chiodini, B. Cianciaruso, A. Pota, V. Bellizzi, G. Tirino, D. Avino, F. Catapano, and R. Minutolo Stability of Target Hemoglobin Levels during the First Year of Epoetin Treatment in Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 938 - 946. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
